Floatz logo

13 assets in Portal Vein Thrombosis

Therapeutic assets addressing Portal Vein Thrombosis, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Lenvatinib
Portal Vein Thrombosis
First Hospital of China Medical UniversityP4BBB (73)
Warfarin
Portal Vein Thrombosis
Kafrelsheikh UniversityP4BB (70)
Nadroparin
Portal Vein Thrombosis
Shanghai Zhongshan HospitalP4BB (68)
Enoxaparin
Portal Vein Thrombosis
Institute of Liver and Biliary Sciences, IndiaP4BB (64)
Apixaban
Portal Vein Thrombosis
Asian Institute Of Medical SciencesP4B (62)
Carvedilol
Portal Vein Thrombosis
Asian Institute Of Medical SciencesP4B (62)
Dabigatran
Portal Vein Thrombosis
Institute of Liver and Biliary Sciences, IndiaP2/3CCC (55)
Atezolizumab
Portal Vein Thrombosis
Third Affiliated Hospital, Sun Yat-Sen UniversityP2CCC (53)
Recombinant Human Adenovirus Type 5
Portal Vein Thrombosis
Tianjin Medical University Cancer Institute and HospitalP2CCC (53)
Tislelizumab
Portal Vein Thrombosis
First Hospital of China Medical UniversityP2CCC (53)
Tuvonralimab
Portal Vein Thrombosis
Nanfang Hospital, Southern Medical UniversityP2CCC (53)
Renvatinib
Portal Vein Thrombosis
First Affiliated Hospital of Guangxi Medical UniversityP1/2CCC (48)
Pembrolizumab
Portal Vein Thrombosis
RenJi HospitalN/AD (30)